|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.059 CHF | +0.34% |
|
+7.27% | +43.90% |
| Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
| Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Spexis AG reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CHF 18.55 million compared to CHF 11.86 million a year ago. Basic loss per share from continuing operations was CHF 0.38 compared to CHF 0.82 a year ago.
Diluted loss per share from continuing operations was CHF 0.38 compared to CHF 0.82 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +43.90% | 4.36M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
SPEXIS AG 
